Today I'll be reading one of my recent newsletters! It's kind of a fun run-down of my anti-azathioprine stance. As I say in the piece, some patients may benefit from azathioprine and I am not saying it is an entirely useless drug or that nobody should ever prescribe it. Rather, I am just saying that it is likely the worst option for nearly every indication for which it could be prescribed.

Please subscribe AND JOIN my newsletter if you would like to support my writing and podcasting! https://t.co/RIzRvWnSfv

Today I review a recent large meta analysis of randomized controlled trials of statin use. Super interesting findings that have changed my clinical practice. Check out the paper here and listen to the episode! 

Paper: https://www.thelancet.com/article/S0140-6736(22)01545-8/fulltext

"Internet driven cult" editorial: https://pubmed.ncbi.nlm.nih.gov/28738422/

Change of pace today! I interviewed Jason Liebowitz and Phil Seo about their new book entitled "Clinical Innovation in Rheumatology: Past, Present, and Future." I thoroughly enjoyed the book and had a great time interviewing them about some of their "futuristic" topics. Grab the book (or better yet, have your division get some copies) at the link below and be sure to share the podcast with friends! 

https://www.routledge.com/Clinical-Innovation-in-Rheumatology-Past-Present-and-Future/Liebowitz-Seo/p/book/9781032074917

Quick episode this week to share an editorial I recently wrote with Jay Patel and Anisha Dua. We cover one of my least phrases in medicine, the "diagnosis of exclusion." 

Hope you enjoy! Find the original paper here: https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keac278/6584804

Exciting (negative) results from a large RCT on the podcast this week as well as a (mini) rant about how we should be spending our time as rheumatologists and the false security of ineffective treatments. 

https://www.nejm.org/doi/full/10.1056/NEJMoa2202106

Interesting case-crossover study today evaluating the association between HCQ dosing and risk of SLE flares. Super worth your time to read the paper or listen to this episode! 

https://jamanetwork.com/journals/jama/article-abstract/2796634

Podcast is back! This week I discuss a pivotal RCT in dermatomyositis. Check it out and be sure to subscribe to my newsletter at ebrheum.com! 

Mixing it up again this week to discuss an editorial by Miguel Hernan and a systematic review of target trials in rheumatology. It's kind of a fun free-form stream of consciousness. Hope you enjoy! Links: 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888052/

https://pubmed.ncbi.nlm.nih.gov/32381560/

Quick episode today. I wanted to share an editorial that was recently published in Rheumatology, where I and co-authors (Shannon Tai and Natalie Anumolu) discuss lessons from recent trials in AAV and SLE. 

Link to editorial: https://pubmed.ncbi.nlm.nih.gov/35438142/ 

After some delay, I finally get around to discussing ORAL-Surveillance, a post-marketing safety study of tofacitinib for rheumatoid arthritis. It's an incredibly important trial that will likely affect how all of us practice for the foreseeable future. Link to paper: 

https://www.nejm.org/doi/full/10.1056/NEJMoa2109927